Synergistic binding of vascular endothelial growth factor-a and its receptors to heparin selectively modulates complex affinity

Journal of Biological Chemistry

Volumn 290, Issue 26, 2015, Pages 16451-16462

  Teran, Madelane ^a   Nugent, Matthew A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Massachusetts Lowell   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENGINEERING; POLYSACCHARIDES; SURFACE PLASMON RESONANCE;

ANGIOGENESIS; BINDING EVENTS; CORECEPTORS; IN-VITRO; PROTEOGLYCANS; STRUCTURAL REQUIREMENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR-A; VEGFR-2;

ENDOTHELIAL CELLS;

HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; NEUROPILIN 1; PROTEIN BINDING; PROTEOHEPARAN SULFATE; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; ANIMAL; CHEMISTRY; GENETICS; KINETICS; METABOLISM;

ANIMALS; ENDOTHELIAL CELLS; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN; HUMANS; KINETICS; MICE; NEUROPILIN-1; PROTEIN BINDING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84941313393     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.627372     Document Type: Article

References (53)

1. Karamysheva, A. (2008) Mechanisms of angiogenesis. Biochemistry 73, 751-762
2. Chung, A. S., and Ferrara, N. (2011) Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27, 563-584
3. Folkman, J. (1995) Angiogenesis incancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31
4. Nagy, J. A., Dvorak, A. M., and Dvorak, H. F. (2007) VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2, 251-275
5. Kerbel, R. S. (2008) Tumor angiogenesis. New Engl. J. Med. 358, 2039-2049
6. Carmeliet, P., and Jain, R. K. (2000) Angiogenesis in cancer and other diseases. Nature 407, 249-257
7. Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature 438, 932-936
8. Kiselyov, A., Balakin, K. V., and Tkachenko, S. E. (2007) VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs 16, 83-107
9. Takahashi, H., and Shibuya, M. (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. 109, 227-241
10. Roy, H., Bhardwaj, S., and Ylä-Herttuala, S. (2006) Biology of vascular endothelial growth factors. FEBS Lett. 580, 2879-2887
11. Robinson, C. J., and Stringer, S. E. (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114, 853-865
12. Guo, P., Xu, L., Pan, S., Brekken, R. A., Yang, S. T., Whitaker, G. B., Nagane, M., Thorpe, P. E., Rosenbaum, J. S., Su Huang, H. J., Cavenee, W. K., and Cheng, S. Y. (2001) Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res. 61, 8569-8577
13. Olsson, A. K., Dimberg, A., Kreuger, J., and Claesson-Welsh, L. (2006) VEGF receptor signalling: in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371
14. Gitay-Goren, H., Soker, S., Vlodavsky, I., and Neufeld, G. (1992) The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 267, 6093-6098
15. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., and Klagsbrun, M. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745
16. Nugent, M. A. (2000) Heparin sequencing brings structure to the function of complex oligosaccharides. Proc. Natl. Acad. Sci. U. S. A. 97, 10301-10303
17. Casu, B., and Lindahl, U. (2001) Structure and biological interactions of heparin and heparan sulfate. Adv. Carbohydr. Chem. Biochem. 57, 159-206
18. Nugent, M. A., Zaia, J., and Spencer, J. L. (2013) Heparan sulfate-protein binding specificity. Biochemistry 78, 726-735
19. Capila, I., and Linhardt, R. J. (2002) Heparin-protein interactions. Angewandte Chemie 41, 391-412
20. Forsten, K. E., Fannon, M., and Nugent, M. A. (2000) Potential mechanisms for the regulation of growth factor binding by heparin. J. Theor. Biol. 205, 215-230
21. Ibrahimi, O. A., Zhang, F., Hrstka, S. C., Mohammadi, M., and Linhardt, R. J. (2004) Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 43, 4724-4730
22. Forsten-Williams, K., Chua, C. C., and Nugent, M. A. (2005) The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. J. Theor. Biol. 233, 483-499
23. He, Z., and Tessier-Lavigne, M. (1997) Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 90, 739-751
24. Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y.-T., Giger, R. J., and Ginty, D. D. (1997) Neuropilin is a semaphorin III receptor. Cell 90, 753-762
25. Whitaker, G. B., Limberg, B. J., and Rosenbaum, J. S. (2001) Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF165 and VEGF121. J. Biol Chem. 276, 25520-25531
26. Carmeliet, P., Ng, Y. S., Nuyens, D., Theilmeier, G., Brusselmans, K., Cornelissen, I., Ehler, E., Kakkar, V. V., Stalmans, I., Mattot, V., Perriard, J. C., Dewerchin, M., Flameng, W., Nagy, A., Lupu, F., Moons, L., Collen, D., D'Amore, P. A., and Shima, D. T. (1999) Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5, 495-502
27. Maes, C., Carmeliet, P., Moermans, K., Stockmans, I., Smets, N., Collen, D., Bouillon, R., and Carmeliet, G. (2002) Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech. Dev. 111, 61-73
28. Stalmans, I., Ng, Y.-S., Rohan, R., Fruttiger, M., Bouché, A., Yuce, A., Fujisawa, H., Hermans, B., Shani, M., Jansen, S., Hicklin, D., Anderson, D. J., Gardiner, T., Hammes, H.-P., Moons, L., Dewerchin, M., Collen, D., xE, sir, xE, Carmeliet, P., and D'Amore, P. A. (2002) Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 109, 327-336
29. Zelzer, E., McLean, W., Ng, Y. S., Fukai, N., Reginato, A. M., Lovejoy, S., D'Amore, P. A., and Olsen, B. R. (2002) Skeletal defects in VEGF (120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 129, 1893-1904
30. Jakobsson, L., Kreuger, J., Holmborn, K., Lundin, L., Eriksson, I., Kjellén, L., and Claesson-Welsh, L. (2006) Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev. Cell 10, 625-634
31. Koch, S., Van Meeteren, L. A., Morin, E., Testini, C., Weström, S., Björkelund, H., Le Jan, S., Adler, J., Berger, P., and Claesson-Welsh, L. (2014) NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation. Dev. Cell 28, 633-646
32. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309
33. Cohen, T., Gitay-Goren, H., Sharon, R., Shibuya, M., Halaban, R., Levi, B. Z., and Neufeld, G. (1995) VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding tothe VEGF receptorsof human melanoma cells. J. Biol. Chem. 270, 11322-11326
34. Dougher, A. M., Wasserstrom, H., Torley, L., Shridaran, L., Westdock, P., Hileman, R. E., Fromm, J. R., Anderberg, R., Lyman, S., Linhardt, R. J., Kaplan, J., and Terman, B. I. (1997) Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. Growth Factors 14, 257-268
35. Chiang, M.-K., and Flanagan, J. G. (1995) Interactions between the Flk-1 receptor, vascular endothelial growth factor, and cell surface proteoglycan identified with a soluble receptor reagent. Growth Factors 12, 1-10
36. Park, M., and Lee, S.-T. (1999) The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem. Biophys. Res. Commun. 264, 730-734
37. Ono, K., Hattori, H., Takeshita, S., Kurita, A., and Ishihara, M. (1999) Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology 9, 705-711
38. Goerges, A. L., and Nugent, M. A. (2003) Regulation of vascular endothelial growth factor binding and activity by extracellular pH. J. Biol. Chem. 278, 19518-19525
39. Zhao, W., McCallum, S. A., Xiao, Z., Zhang, F., and Linhardt, R. J. (2012) Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides. Biosci. Rep. 32, 71-81
40. Rahimi, N., Dayanir, V., and Lashkari, K. (2000) Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J. Biol. Chem. 275, 16986-16992
41. Singh, A. J., Meyer, R. D., Band, H., and Rahimi, N. (2005) The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Mol. Biol. Cell 16, 2106-2118
42. Xu, D., Fuster, M. M., Lawrence, R., and Esko, J. D. (2011) Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability. J. Biol Chem. 286, 737-745
43. Day, E. S., Capili, A. D., Borysenko, C. W., Zafari, M., and Whitty, A. (2013) Determining the affinity and stoichiometry of interactions between unmodified proteins in solution using Biacore. Anal. Biochem. 440, 96-107
44. Ashikari-Hada, S., Habuchi, H., Kariya, Y., and Kimata, K. (2005) Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells: comparison of the effects of heparin and modified heparins. J. Biol. Chem. 280, 31508-31515
45. Hamma-Kourbali, Y., Vassy, R., Starzec, A., Le Meuth-Metzinger, V., Oudar, O., Bagheri-Yarmand, R., Perret, G., and Crepin, M. (2001) Vascular Endothelial Growth Factor 165 (VEGF165) Activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF165 and VEGF165-KDR complexes. J. Biol. Chem. 276, 39748-39754
46. Vander Kooi, C. W., Jusino, M. A., Perman, B., Neau, D. B., Bellamy, H. D., and Leahy, D. J. (2007) Structural basis for ligand and heparin binding to neuropilin B domains. Proc. Natl. Acad. Sci. U. S. A. 104, 6152-6157
47. Ellis, L. M., and Hicklin, D. J. (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591
48. Grünewald, F. S., Prota, A. E., Giese, A., and Ballmer-Hofer, K. (2010) Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim. Biophys. Acta 1804, 567-580
49. Fong, G.-H., Rossant, J., Gertsenstein, M., and Breitman, M. L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70
50. Cao, Y. (2009) Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2, re1
51. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., and Shibuya, M. (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 95, 9349-9354
52. Morimoto-Tomita, M., Uchimura, K., Werb, Z., Hemmerich, S., and Rosen, S. D. (2002) Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J. Biol. Chem. 277, 49175-49185
53. Uchimura, K., Morimoto-Tomita, M., Bistrup, A., Li, J., Lyon, M., Gallagher, J., Werb, Z., and Rosen, S. (2006) HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem. 7, 2